The authors concluded that the anti-CD22 CAR-T lymphocytes are highly helpful in achieving a positive remission status in relapsed B-ALL patients, even in those who have previously received anti-CD19 CAR-T therapy [90]. This evidence concerns the gene CD22 and precursor B-cell acute lymphoblastic leukemia.